16 Sudro Hall
Pharmacogenomics (PSCI417) and Neuropharmacology (PSCI 416) for Pharm D students.
Targeting Angiotensin Converting Enzyme-2 (ACE2)/Angiotensin-(1-7) System in Bone Marrow-Derived Cells for Vascular Repair in Diabetes.
Targeting Leptin Receptor for Diabetic Bone Marrow Mobilopathy.
2002 Ph.D. Glasgow Caledonian University, UK
1998 M.Sc. University of Strathclyde, UK
1993 M.Pharm. Andhra University, India
1990 B.Pharm Andhra University, India
2003 and 2006 ASPET Travel Awards.
2001 British Pharmacological Society Travel Award for Pharmacology-2001, Vancouver, Canada.
2001 European Society for Hypertension Travel Award.
2001 Federation of European Pharmacological Societies (EPHAR) Travel Award.
1997 Academy of Commonwealth Universities (ACU) and Oversees Development Administration (ODA) Shared Scholarship.
1991 University Grants Commission (UGC) Fellowship.
1991 Indian Drug Manufacturers Association (IDMA), G.P.Nair Award.
2008-2011 Asst. Instructor, Pharmacology & Therapeutics, University of Florida, Gainesville, FL.
2005-2007 Part-Time, Technology-Scientist, Danish MyoTechnology-USA, Inc.
2005-2007 Post-Doctoral Associate, Wake Forest University, Winston-Salem NC.
2002-2004 Post-Doctoral Associate, Pharmacology & Therapeutics, University of Florida, Gainesville, FL.
1995-1997 Sr. Pharmacologist, Dr. Reddy’s Research Foundation, Hyderabad, India.
2011 to date Member of American Association of Colleges of Pharmacy (AACP).
2007 to date Professional member of American Heart Association (AHA).
2002 to date Regular member of American Society of Pharmacology and
Experimental Therapeutics (ASPET).
2006-2011 Member of the Association for Research in Vision and
1998-2007 Regular member of the British Pharmacological Society (BPS).
1998-2004 Member of British Physiological Society.
1995-1997 Member of Indian Pharmacological Society (IPS).
Life member Indian Pharmaceutical Graduates Association (IPGA).
Vasam G, Joshi S, Thatcher SE, Bartelmez SH, Cassis LA, Jarajapu YP. (2017). Reversal of bone marrow mobilopathy and enhanced vascular repair by Angiotensin-(1-7) in diabetes. Diabetes. 66(2):505-518.
Vasam G, Joshi S, Jarajapu YP. Impaired mobilization of vascular reparative bone marrow cells in streptozotocin-induced diabetes but not in leptin receptor-deficient db/db mice. Sci Rep. 2016;6:26131. Doi: 10.1038/srep26131.
Singh N, Joshi S, Guo L, Baker MB, Li Y, Castellano RK, Raizada MK, Jarajapu YP. (2015). ACE2/Ang-(1-7)/Mas axis stimulates vascular repair-relevant functions of CD34+ cells. Am J Physiol Heart Circ Physiol. 309(10):H1697-707.
Jarajapu YP, Hazra S, Segal M, LiCalzi S, Jhadao C, Qian K, Mitter SK, Raizada MK, Boulton ME, Grant MB. (2014). Vasoreparative dysfunction of CD34+ cells in diabetic individuals involves hypoxic desensitization and impaired autocrine/paracrine mechanisms. PLoS One. 9(4):e93965.
Jarajapu et al (2013). Activation of the ACE2/Angiotensin-(1-7)/Mas receptor axis enhances the reparative function of dysfunctional diabetic endothelial progenitor cells. Diabetes. 62(4):1258-69.
Follow this link for the full list of publications: http://www.ncbi.nlm.nih.gov/pubmed?term=yagna%20OR%20jarajapu
Current Funding Support
National Institutes of Health and American Heart Association.